$Coya Therapeutics (COYA.US)$ NEWS Coya Therapeutics Present...
NEWS
Coya Therapeutics Presents Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium
Serum 4-HNE levels in ALS patients correlate with disease progression and survival, with higher levels indicating faster progression and shorter survival. The ROC analysis shows 100% sensitivity for a 21-month survival threshold, making it a potential biomarker for ALS. The presentation at the Johnson Center Symposium highlighted the predictive value of 4-HNE in assessing clinical status and disease progression in ALS patients.
Serum 4-HNE levels in ALS patients correlate with disease progression and survival, with higher levels indicating faster progression and shorter survival. The ROC analysis shows 100% sensitivity for a 21-month survival threshold, making it a potential biomarker for ALS. The presentation at the Johnson Center Symposium highlighted the predictive value of 4-HNE in assessing clinical status and disease progression in ALS patients.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment